Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze PHAT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate PHAT investment potential.

What is PHAT stock price today?

Get real-time PHAT stock price, historical data, and price charts on Financhill. Track PHAT performance with our advanced analysis tools.

Is PHAT a good investment?

Evaluate PHAT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy PHAT stock?

To buy PHAT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of PHAT?

View detailed market capitalization data and company valuation metrics for PHAT on our comprehensive analysis page.

What is the P/E ratio of PHAT?

Use our fundamental analysis tools to view PHAT P/E ratio and compare valuation metrics with industry peers.

What are PHAT earnings?

View PHAT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Phathom Pharmaceuticals, Inc. Stock Predictions

Valuation Up 5,000%. Shares Now $0.85 - Still Early?

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Sell

PHAT
Phathom Pharmaceuticals, Inc.

Last Price:

$14.70

Seasonality Move:

-8.81%

7 Day Trial

ALL ACCESS PASS

$ 7

14K Investors Got In Earlier. You Still Can.

Phathom Pharmaceuticals, Inc. Stock Forecast

Over the next 52 weeks, Phathom Pharmaceuticals, Inc. has on average historically risen by 8.7% based on the past 6 years of stock performance.
Phathom Pharmaceuticals, Inc. has risen higher in 3 of those 6 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Is Phathom Pharmaceuticals, Inc. Stock Undervalued?

The current Phathom Pharmaceuticals, Inc. [PHAT] share price is $14.56. The Score for PHAT is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.
PHAT is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Phathom Pharmaceuticals, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Phathom Pharmaceuticals, Inc. has on average historically risen by 8.7% based on the past 6 years of stock performance.

Phathom Pharmaceuticals, Inc. Stock Rating

Sell

Phathom Pharmaceuticals, Inc. (PHAT) is a Sell

Is Phathom Pharmaceuticals, Inc. overpriced?

Phathom Pharmaceuticals, Inc. has risen higher in 3 of those 6 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

Phathom Pharmaceuticals, Inc. Stock Price History

Is PHAT stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and PHAT is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Pharmaceuticals

Sector:

Health Care

Type:

stock

Website:

phathompharma.com

52-Week Data

52-Week High:

16.45

52-Week Low:

2.21

Prediction Charts

Market Cap:

Price in USD:

14.56

Volume:

1.2M

Beta:

0.80

Technical Analysis

SMA50:

13.79

SMA100:

12.35

SMA200:

9.21

52-Wk Change:

82.34%

Stock Predictions

Is Phathom Pharmaceuticals, Inc. stock public?

Yes, Phathom Pharmaceuticals, Inc. is a publicly traded company.
What is the Phathom Pharmaceuticals, Inc. stock quote today?

The Phathom Pharmaceuticals, Inc. stock price is 14.56 USD today.
How to buy Phathom Pharmaceuticals, Inc. stock online?

You can buy Phathom Pharmaceuticals, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Nov-24	14.69	14.82	15.24	14.61
Nov-25	14.83	14.93	15.12	14.61
Nov-26	15.05	15.17	15.32	14.87
Nov-28	15.41	15.62	16.27	15.21
Dec-1	15.34	14.94	15.61	14.85
Dec-2	14.97	14.74	15.16	14.62
Dec-3	14.90	14.67	15.16	14.45
Dec-4	14.67	14.70	14.91	14.27
Dec-5	14.69	14.58	14.85	14.12
Dec-8	14.80	14.90	15.14	14.55
Dec-9	15.03	14.21	15.14	14.19
Dec-10	14.20	14.55	14.64	14.12
Dec-11	14.62	14.57	14.79	14.46
Dec-12	15.22	14.56	16.45	14.51

Phathom Pharmaceuticals, Inc. Earnings

Phathom Pharmaceuticals, Inc. Earnings Report: Per Share Phathom Pharmaceuticals, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Phathom Pharmaceuticals, Inc. Forecast Revenue Growth

Phathom Pharmaceuticals, Inc. Stock Analysis: Historical quarterly revenues per share for Phathom Pharmaceuticals, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.41 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.35 per share, and an increase next year of $2.25 per share.

* Phathom Pharmaceuticals, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.